PARSIPPANY, N.J., Feb. 10, 2017 /PRNewswire/ — Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that its President & Chief Executive Officer, Jack E. Stover, will deliver a corporate presentation at the 2017 BIO CEO & Investor Conference, being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York.
Details for this presentation are as follows:
- 2017 BIO CEO & Investor Conference – webcast available
- Time/Date: 4:30 pm ET on Monday, February 13, 2017
- Location: Waldorf Astoria Hotel, New York
Presentation Room: Conrad Room
A live webcast of Interpace Diagnostics’ presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2017/69132493167.cfm. A replay will be archived and accessible for 90 days at the same website.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace’s mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics’ website at www.interpacediagnostics.com.
407.644.4256, ext. 111